HICON (sodium iodide i 131) by Jubilant Therapeutics is sodium-iodide symporter (nis) protein, in thyroid follicular cells. First approved in 2003.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
HICON (Sodium Iodide I-131) is an oral radioactive iodine solution that treats thyroid cancer and hyperthyroidism by concentrating in thyroid follicular cells via the sodium-iodide symporter and delivering targeted beta radiation. The iodide is oxidized and incorporated into thyroglobulin, with the beta emission providing the therapeutic cytotoxic effect. This is a well-established nuclear medicine product with decades of clinical use.
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling smaller commercial teams and focus on defensive positioning rather than growth.
sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I) which in turn iodinates tyrosine residues of thyroglobulin (tri…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers
Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia
Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence
Worked on HICON at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on HICON offers limited career growth due to zero linked job postings and approaching loss of exclusivity; roles are primarily defensive and operationally focused. Professionals should expect smaller teams, commoditized competition, and a transition toward cost management and compliance rather than market expansion.